Treatment modalities for limited-stage small-cell esophageal cancer: an analysis of 121 patients

王军,焦文鹏,曹峰,刘青,王祎,景绍武,杨从容,程云杰

DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2016.07.008

2016-01-01

Abstract:Objective To investigate the treatment modalities and prognostic factors for primary limited-stage small-cell esophageal cancer.Methods A retrospective analysis was performed in 121 patients with limited-stage small-cell esophageal cancer.In 98 patients undergoing surgery,37 received surgery alone,40 received surgery plus chemotherapy,and 21 received surgery plus chemoradiotherapy.In 23 patients receiving nonsurgical treatment,18 received chemoradiotherapy and 5 received chemotherapy alone.Survival rate was caculated with Kaplan-Meier method and log-rank test.Multivariate analysis of prognostic factors in Cox model.Results There were no significant differences in 1-,3-year overall survival (OS) rates between the surgery group and the non-surgery group (88％ vs.78％,37％ vs.43％;P=0.585).In the surgery group,there was no significant difference in LC rate between patients undergoing different treatment modalities (P=0.113);the surgery plus chemotherapy group and the surgery plus chemoradiotherapy group had significantly higher OS rates than the surgery alone group (P=0.002,P=0.028);there were no significant differences in the 1-,3-year OS rates between the surgery plus chemotherapy group and the surgery plus chemoradiotherapy group (88％ vs.83％,44％ vs.50％;P=0.969).Patients undergoing ≥ 4 cycles of chemotherapy had significantly higher 1-,3-year OS rates than those undergoing＜4 cycles of chemotherapy (89％ vs.85％,53％vs.35％;P=0.036).The multivariate analysis showed that chemotherapy was an independent factor for survival in patients with limited-stage small-cell esophageal cancer (P=0.006).Conclusions Patients undergoing surgery alone for limited-stage small-cell esophageal cancer have a poor prognosis.Compared with radiotherapy,surgery combined with systemic chemotherapy is not able to substantially improve local control and prognosis.Chemotherapy is an independent factor for survival in patients with limited-stage small-cell esophageal cancer.At least 4 cycles of chemotherapy are recommended.